Ownership history in William Allan Corp Β· 7 quarters on record
This page tracks every 13F SEC filing in which William Allan Corp reported a position in WEST PHARMACEUTICAL SVSC INC (WST). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π William Allan Corp underperformed the S&P 500 by β15.5% annually on this WST position. Timing score: 40% (2/5 decisions correct). Average cost basis: $250.63. Maximum drawdown during holding period: β33.1%.
β Significantly underperformed the S&P 500 by 15.5% ann.
5 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
2 of 5 add/trim decisions correct
Best entry: $218.25 (2025 Q2) Β· Worst: $326.20 (2024 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
5 adds Β· 2 trims. Bought during 2 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π William Allan Corp has been actively increasing its WST allocation β a bullish signal from insiders.
Currently 2.05% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size